Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: Case report and review of the literature

Transplant Infectious Disease

Volumn 15, Issue 6, 2013, Pages

  Verkaik, N J ^a   Hoek, R A S ^a   van Bergeijk, H ^a   van Hal, P Th W ^a   Schipper, M E I ^a   Pas, S D ^a   Beersma, M F C ^a   Boucher, C A B ^a   Jedema, I ^b   Falkenburg, F ^b   Hoogsteden, H C ^a   van den Blink, B ^a   Murk, J L ^a,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

CMV; Cytomegalovirus; Foscarnet; Ganciclovir; Leflunomide; Lung transplant; Multidrug resistant

Indexed keywords

BASILIXIMAB; CIDOFOVIR; CYTOMEGALOVIRUS ANTIBODY; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN G; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; VALGANCICLOVIR;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; CELL INCLUSION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLON BIOPSY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAINTENANCE DRUG DOSE; ORGAN DONOR; PRIORITY JOURNAL; PROPHYLAXIS; SEQUENCE ANALYSIS; VIREMIA; VIRUS LOAD; VIRUS STRAIN; VOMITING;

CMV; CYTOMEGALOVIRUS; FOSCARNET; GANCICLOVIR; LEFLUNOMIDE; LUNG TRANSPLANT; MULTIDRUG RESISTANT;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FOSCARNET; GANCICLOVIR; HUMANS; IMMUNOGLOBULINS; ISOXAZOLES; LUNG TRANSPLANTATION; MIDDLE AGED; VIRAL LOAD;

EID: 84888869319     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12156     Document Type: Article

References (29)

1. Zamora MR. Cytomegalovirus and lung transplantation. Am J Transplant 2004; 4: 1219-1226.
2. Snyder LD, Finlan-Copeland CA, Turbyfill WJ, et al. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med 2010; 181: 1391-1396.
3. Weigt SS, Elashoff RM, Keane MP, et al. Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation. Am J Transplant 2008; 8: 1512-1522.
4. Strasfeld L, Lee I, Tatarowicz W, et al. Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir. J Infect Dis 2010; 202: 104-108.
5. Avery RK, Mossad SB, Poggio E, et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation 2010; 90: 419-426.
6. Hertz MI, Aurora P, Christie JD, et al. Scientific Registry of the International Society for Heart and Lung Transplantation: introduction to the 2010 annual reports. J Heart Lung Transplant 2010; 29: 1083-1088.
7. Van Doornum GJ, Guldemeester J, Osterhaus AD, et al. Diagnosing herpesvirus infections by real-time amplification and rapid culture. J Clin Microbiol 2003; 41: 576-580.
8. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
9. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbial Rev 2010; 23: 689-712.
10. Chacko B, John GT. Leflunomide for cytomegalovirus: bench to bedside. Transpl Infect Dis 2012; 14: 111-120.
11. Lurain NS, Bhorade SM, Pursell KJ, et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis 2002; 186: 760-768.
12. Balthesen M, Messerle M, Reddehase MJ. Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol 1993; 67: 5360-5366.
13. Limaye AP, Raghu G, Koelle DM, et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185: 20-27.
14. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-795.
15. Razonable RR, Humar A; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2013; 13: 93-106.
16. Chong AS, Finnegan A, Jiang X, et al. Leflunomide, a novel immunosuppressive agent. The mechanism of inhibition of T cell proliferation. Transplantation 1993; 55: 1361-1366.
17. Siemasko K, Chong ASF, Jäck HM, et al. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol 1998; 160: 1581-1588.
18. Williams JW, Mital D, Chong A, et al. Experiences with leflunomide in solid organ transplantation. Transplantation 2002; 73: 358-366.
19. Waldmann WJ, Knight DA, Lurain NS, et al. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation 1999; 68: 814-825.
20. John GT, Manivannan J, Chandy S, et al. Leflunomide therapy for cytomegalovirus disease in renal allograft recipients. Transplantation 2004; 77: 1460-1461.
21. Avery RK, Bolwell BJ, Yen-Lieberman B, et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant 2004; 34: 1071-1075.
22. John GT, Manivannan J, Chandy S, et al. A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients. Transplant Proc 2005; 37: 4303-4305.
23. Levi ME, Mandava N, Chan LK, Weinberg A, Olson JL. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl Infect Dis 2006; 8: 38-43.
24. Ehlert K, Groll AH, Kuehn J, et al. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide. Klin Padiatr 2006; 218: 180-184.
25. Andrassy J, Illner WD, Rentsch M, et al. Leflunomide: a treatment option for ganciclovir-resistant cytomegalovirus infection after renal transplantation. NDT Plus 2009; 2: 149-151.
26. Goldsmith PM, Husain MM, Carmichael A, et al. Multidrug-resistant cytomegalovirus in a modified multivisceral transplant recipient. Transplantation 2012; 93: e30-e32.
27. Battiwalla M, Paplham P, Almyroudis NG, et al. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. Transpl Infect Dis 2007; 9: 28-32.
28. Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci USA 2000; 97: 8039-8044.
29. Zandvliet ML, Van Liempt E, Jedema I, et al. Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy. Cytotherapy 2010; 12: 933-944.